These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1296 related items for PubMed ID: 18471512

  • 21. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P.
    Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
    [Abstract] [Full Text] [Related]

  • 22. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.
    J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
    [Abstract] [Full Text] [Related]

  • 23. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome.
    Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S, Teuber P, Terlipressin Study Group.
    Gastroenterology; 2008 May; 134(5):1360-8. PubMed ID: 18471513
    [Abstract] [Full Text] [Related]

  • 24. [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
    Nguyen-Tat M, Götz E, Scholz-Kreisel P, Ahrens J, Sivanathan V, Schattenberg J, Rey JW, Wörns MA, Galle PR, Marquardt JU.
    Dtsch Med Wochenschr; 2015 Jan; 140(2):e21-6. PubMed ID: 25612289
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Krag A, Borup T, Møller S, Bendtsen F.
    Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
    [Abstract] [Full Text] [Related]

  • 26. Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation.
    Caraceni P, Santi L, Mirici F, Montanari G, Bevilacqua V, Pinna AD, Bernardi M.
    Dig Liver Dis; 2011 Mar; 43(3):242-5. PubMed ID: 20833118
    [Abstract] [Full Text] [Related]

  • 27. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes.
    Rodriguez E, Henrique Pereira G, Solà E, Elia C, Barreto R, Pose E, Colmenero J, Fernandez J, Navasa M, Arroyo V, Ginès P.
    Liver Transpl; 2015 Nov; 21(11):1347-54. PubMed ID: 26178066
    [Abstract] [Full Text] [Related]

  • 28. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
    Singh V, Kumar R, Nain CK, Singh B, Sharma AK.
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):303-7. PubMed ID: 16460491
    [Abstract] [Full Text] [Related]

  • 29. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B, Ardizzone G, Valente U.
    Hepatogastroenterology; 2003 Jan; 50(54):1753-5. PubMed ID: 14696397
    [Abstract] [Full Text] [Related]

  • 30. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF.
    Gastroenterology; 2002 Apr; 122(4):923-30. PubMed ID: 11910344
    [Abstract] [Full Text] [Related]

  • 31. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.
    Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, Antona C, Brollo L, Franchin M, Cillo U, Merkel C, Gatta A.
    Aliment Pharmacol Ther; 2006 Jan 01; 23(1):75-84. PubMed ID: 16393283
    [Abstract] [Full Text] [Related]

  • 32. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C, Einstein M, Lucey MR, Said A.
    J Clin Gastroenterol; 2009 Aug 01; 43(7):680-5. PubMed ID: 19238094
    [Abstract] [Full Text] [Related]

  • 33. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
    Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, Pereira G, Poca M, Sánchez J, Guevara M, Soriano G, Alessandria C, Fernández J, Arroyo V, Ginès P.
    J Hepatol; 2014 May 01; 60(5):955-61. PubMed ID: 24447876
    [Abstract] [Full Text] [Related]

  • 34. A study on clinical outcomes of combination of terlipressin and albumin in Hepatorenal Syndrome.
    Krishna R, Raj J, Dev D, Prasad SC, Reghu R, V SO.
    Scand J Gastroenterol; 2020 Jul 01; 55(7):860-864. PubMed ID: 32634332
    [Abstract] [Full Text] [Related]

  • 35. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study.
    Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, Sharma N, Bhalla A, Chawla YK, Singh V.
    Liver Int; 2013 Sep 01; 33(8):1187-93. PubMed ID: 23601499
    [Abstract] [Full Text] [Related]

  • 36. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
    Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K.
    J Gastroenterol; 2012 Mar 01; 47(3):313-20. PubMed ID: 22038555
    [Abstract] [Full Text] [Related]

  • 37. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study.
    Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, Sharma AK, Choudhary NS, Chawla Y, Nain CK.
    J Hepatol; 2012 Jun 01; 56(6):1293-8. PubMed ID: 22322237
    [Abstract] [Full Text] [Related]

  • 38. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K.
    Aliment Pharmacol Ther; 2017 Jun 01; 45(11):1390-1402. PubMed ID: 28370090
    [Abstract] [Full Text] [Related]

  • 39. Terlipressin may influence the outcome of hepatorenal syndrome complicating alcoholic hepatitis.
    Cervoni JP, Lecomte T, Cellier C, Auroux J, Simon C, Landi B, Gadano A, Barbier JP.
    Am J Gastroenterol; 1997 Nov 01; 92(11):2113-4. PubMed ID: 9362205
    [Abstract] [Full Text] [Related]

  • 40. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE, Alcalá EG, Cordero P, Martínez MA, Vázquez NY, Galindo S, Mendoza E, Segura JJ.
    Ann Hepatol; 2009 Nov 01; 8(3):207-11. PubMed ID: 19841499
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 65.